Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)

İÇLİ F., Altundag K., AKBULUT H., PAYDAŞ S., BAŞARAN G., Saip P., ...More

BREAST CANCER, vol.22, no.5, pp.480-485, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 5
  • Publication Date: 2015
  • Doi Number: 10.1007/s12282-013-0506-y
  • Journal Name: BREAST CANCER
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.480-485
  • Keywords: Adjuvant treatment, Nine weeks trastuzumab, Cardiotoxicity, Early breast cancer, CHEMOTHERAPY, XENOGRAFTS, ANTIBODY, RECEPTOR, THERAPY
  • Dokuz Eylül University Affiliated: Yes


Background Optimal duration of adjuvant trastuzumab in early breast cancer is an unresolved issue. In this observational study, we compared the outcome of 9 weeks and 1 year adjuvant trastuzumab in early breast cancer patients in Turkey.